A vicious cycle of karyopherin abnormalities in synucleinopathies
Objective: This study aims to investigate the role of karyopherin abnormalities in the onset and progression of synucleinopathies. Background: Despite differences in clinical manifestations, Parkinson’s…Diagnostic Utility of Blood α-Synuclein in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: The aims were to (1) explore the concentration differences of α-syn species in different blood components between PD and healthy controls (HC), and between…The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease.
Objective: Alpha synuclein aggregation have been indicted in the process of neuronal cell loss in Parkinson's disease; however, there have been several hypothesis to explain…Parkinson’s disease in patients with Gaucher’s disease – causation or association?
Objective: To do a systematic review to find the risk of Parkinson's disease in patients with Gaucher’s disease. Background: Parkinson's disease (PD) is the second…TREM2 maintain microglial proliferation and α-syn accumulation in PD models via the PI3K-Akt pathway
Objective: To investigate the effect and role of TREM2 in microglial proliferation, α-syn-associated pathology and dopaminergic degeneration in Parkinson’s disease (PD). Background: PD is characterised…Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease
Objective: To present first-in-patient data of the oligomer modulator anle138b (TEV-56286, emrusolmin) in patients with Parkinson’s disease (PD). Background: Synucleinopathies such as PD and Multiple…Impaired lysophagy function exacerbates propagation of α-synuclein aggregation
Objective: We aimed to clarify how exogenous αSyn aggregates interact with native αSyn in the cytoplasm and seed aggregation, and what defense mechanisms protect against…Pathological findings in a case of DJ-1 early onset Parkinson’s disease
Objective: To report the postmortem findings in a case of early onset genetically confirmed DJ-1 (PARK7) PD. Background: As a very rare cause (1-2%) of…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson’s disease: comparison with plasma miRNA
Objective: To identify differentially expressed small extracellular vesicles (sEV) derived miRNAs in Parkinson’s disease using small RNA-sequencing and to evaluate their potential as biomarker targets.…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 51
- Next Page »